BAXBaxter International
$24.36+3.0% 1Y
$24.36
$15.7952 weeks$28.35
The financials
Baxter International by the numbers
Baxter International (BAX) reported revenue of $2.96B in Q2 2026 (quarter ended Jun 30, 2026), up 5.3% from the same quarter a year earlier. That came with a gross margin of 35% and net income of $126M (4.3% of revenue). For the full year FY2025, revenue was $11.2B (+5.7% year on year) and net income −$957M. Its largest product in Q2 2026 was Infusion Therapies And Platforms at $769M, 50% of the disclosed total, well ahead of Care And Connectivity Solutions at 23%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $2.96B | $2.81B | +5.3% |
| Gross profit | $1.03B | $991M | +4.1% |
| Operating income | $217M | $191M | +14% |
| Net income | $126M | $91M | +38% |
| Diluted EPS | $0.24 | $0.18 | +33% |
| Product | Revenue | Share |
|---|---|---|
| Infusion Therapies And Platforms | $769M | 50% |
| Care And Connectivity Solutions | $361M | 23% |
| Front Line Care | $226M | 15% |
| Advanced Surgery | $182M | 12% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.54B (+11%)
Advanced Surgery grew +15% year on yearInfusion Therapies And Platforms +2.1% year on year
Segment Latestquarter on quarteryear on year
- Infusion Therapies And Platforms$769.0M$769.0Mquarter on quarter n/ayear on year +2.1%n/a+2.1%
- Care And Connectivity Solutions$361.0M$361.0Mquarter on quarter +15%year on year +5.9%+15%+5.9%
- Front Line Care$226.0M$226.0Mquarter on quarter +14%year on year +2.3%+14%+2.3%
- Advanced Surgery$182.0M$182.0Mquarter on quarter +10%year on year +15%+10%+15%
On our screens:Stocks with no debt
Medical Instruments & Supplies
The closest names by size in the same industry